MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
On August 10, 2026, MoonLake Immunotherapeutics, a biotechnology company trading on NASDAQ under the symbol MLTX, shared promising findings from the Phase 3 IZAR-1 trial for sonelokimab. The study targeted biologic-naïve adults grappling with active psoriatic arthritis (PsA). The results were positive. Additionally, the company disclosed its financial performance for the second quarter of 2026 in Zug, Switzerland. MoonLake specializes in developing advanced treatments for inflammatory conditions.